A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 106th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 70th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 136th largest by enrollment of the 141 interventional ones that give a count, is one of 37 that started in 2012, is one of 85 in phase 3, and was the 158th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, single arm, interventional, long-term extension (LTE) study will evaluate the safety and efficacy of tocilizumab (TCZ, RoActemra/Actemra) in French participants with moderate to severe RA who have completed the Week 97 visit of WA22762 LTE study (NCT01194414) (EudraCT Number 2010-018375-22). Participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in disease activity score based on 28-joint count [DAS28] of greater than [>] 1.2 points) will continue TCZ treatment within this local LTE study for a maximum of 156 weeks of subcutaneous (SC) TCZ treatment, or until SC TCZ becomes commercially available, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of \>1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.
Drug: Tocilizumab
Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
Also known as: RoActemra, Actemra
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who was administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. A SAE was any untoward medical occurrence that at any dose resulted in death, was life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity, and congenital anomaly/birth defect. AEs included SAEs as well as non-serious AEs.
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With AEs and SAEs Related to TCZ
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included SAEs as well as non-serious AEs. Causality of AEs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on drug cessation \[DC\], relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AEs with causality of certain, probable/likely, and possible were considered TCZ related.
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With Adverse Events of Special Interest (AESIs)
Adverse events of special interest (AESI) for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events.
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With AESIs Related to TCZ
AESI for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events. Percentage of participants with AESI related to the drug were presented. Causality of AESIs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on DC, relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AESIs with causality of certain, probable/likely, and possible were considered TCZ related.
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With AEs Leading to TCZ Discontinuation, Interruption, or Dose Modification
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Percentage of participants with AE causing drug discontinuation, interruption and increase or decrease in dose of drug was presented.
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With Clinically Significant Physical Examinations and Vital Signs Abnormalities
Criteria for potentially clinically important (PCI) change in vital signs: heart rate value of less than (\<) 40 beats per minute and value greater than (\>) 150 beats per minute, systolic blood pressure (SBP) of \< 80 or \>210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of \<40 or \>130 mmHg, body temperature \<32 or \> 40 degrees Celsius, respiratory rate of \<10 or \> 50 breaths/minute and criteria for PCI change in physical examination: \>/=10% increase or decrease of body weight in kilograms (kg).
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With Clinically Significant Laboratory Abnormalities
Criteria for laboratory tests clinically significant abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(\< 0.8\*lower limit of normal\[LLN\]); leucocytes (\<0.6/greater than \[\>\]1.5\*upper limit of normal \[ULN\]); platelets (\<0.5\*LLN\>\</0\>1.75\*ULN); neutrophils, lymphocytes (\<0.8\*LLN\>\</0\>1.2\*ULN); eosinophils, basophils, monocytes (\>1.2\*ULN); total bilirubin, direct bilirubin, indirect bilirubin (\>1.5\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (\>3\*ULN), total protein, albumin (\<0.8\*LLN\>\</0\>1.2\*ULN); creatinine, urea (\>1.3\*ULN); glucose (\<0.6\*LLN\>\</0\>1.5\*ULN); uric acid (\>1.2\*ULN); sodium, potassium, chloride, calcium, bicarbonate (\<0.9\*LLN\>\</0\>1.1\*ULN); urine RBCs, urine white blood cells (WBCs) (\> or equal\[=\]20 high-powered field), urine bacteria \>20 high-powered field. Overall percentage of participants with any clinically significant laboratory abnormality was reported.
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With Anti-TCZ Antibodies
Time frame: Baseline up to approximately 142 weeks
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score
The DAS 28 ESR score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment (PtGA) of disease activity (visual analog scale \[VAS\]: 0 millimeter \[mm\] = no disease activity to 100 mm=maximum disease activity) and the erythrocyte sedimentation rate (ESR in millimeters per hour \[mm/hr\]). DAS28 was calculated using following formulas: DAS28-ESR = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt (SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PtGA of disease activity. A total possible score of 0 to approximately 10, with higher score indicating more severe disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in Simplified Disease Activity Index (SDAI) Score
The SDAI was calculated as (SJC \[28 joints\] + TJC \[28 joints\] + VAS ptGA + VAS physician global assessment of disease activity + C-reactive Protein (CRP) level in milligram/deciliter \[mg/dL\]). VAS assessments: 0 centimeters (cm)=no disease activity to 10 cm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in TJC
For TJC a total of 28 joints were assessed. The presence of a tender joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no tender joint) to 28 (worse possible score or all tender joints). Lower scores indicate no tender joint and higher scores indicate worsening tender joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in SJC
For SJC, a total of 28 joints were assessed. The presence of a swollen joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no swollen joint) to 28 (worse possible score or all swollen joints). Lower scores indicate no swollen joint and higher scores indicate worsening swollen joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Percentage of Participants With Clinical Remission
Clinical remission defined as:DAS28-ESR score \< 2.6 and/or SDAI score \</= 3.3.DAS28 score is measure of subject's disease activity calculated using TJC \[28 joints\],SJC \[28 joints\],PtGA of disease activity \[ VAS:0mm= no disease activity to 100 mm=maximum disease activity\] and ESR (mm/hr). DAS28 was calculated as DAS28-ESR = 0.56\*sqrt (TJC28) + 0.28\*sqrt(SJC28) + 0.70\* ln ESR + 0.014\*PtGA of disease activity. DAS28-ESR score ranged from 0 to approximately 10, higher score indicating more severe disease activity. SDAI was calculated =\[SJC (28 joints) + TJC (28 joints) + VAS PtGA + VAS physician global assessment of disease activity+CRP level(mg/dL)\]. VAS assessments:0 mm=no disease activity to 100 mm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity.
Time frame: Week 48, 108
Percentage of Participants With Concomitant Corticosteroid Discontinuation
Time frame: Baseline up to approximately 142 weeks
Percentage of Participants With Concomitant Corticosteroid Dose Reduction
Time frame: Baseline up to approximately 142 weeks
Time to Concomitant Corticosteroid Discontinuation
Time to corticosteroid discontinuation = (End date of corticosteroid treatment - date of first drug intake of this extension study) + 1.
Time frame: Baseline up to approximately 142 weeks
Time to Concomitant Corticosteroid Dose Reduction
Time to corticosteroid dose reduction (days) = (Date of the first dose reduction of corticosteroid treatment - date of first drug intake of this extension study) + 1.
Time frame: Baseline up to approximately 142 weeks
Change From Baseline in PtGA of Disease Activity
PtGA of disease activity over the previous 24 hours using a 100 mm VAS where left end of the line 0 mm =no disease activity and right end of the line 100 mm =maximum disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in Patient's Assessment of Pain
Patient's assessment of pain over the previous 24 hours: using a VAS, left end of the line 0 mm=no pain to right end of the line 100 mm=unbearable pain. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in Physician's Global Assessment of Disease Activity
The Physician's Global Assessment of disease activity was assessed using a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity". Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in ESR
Blood samples were collected for ESR, which is an acute phase reactant and provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeters per hour (mm/hr). A decrease in the level indicates reduction in inflammation and therefore improvement. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Change From Baseline in CRP
Blood samples were collected for CRP, which is an acute phase reactant and a measure of inflammation. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
A total of 12 participants were screened at 6 sites in France, of which 11 participants were enrolled.
| Milestone | Tocilizumab |
|---|---|
| Started | 11 |
| Completed | 9 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 1 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who was administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. A SAE was any untoward medical occurrence that at any dose resulted in death, was life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity, and congenital anomaly/birth defect. AEs included SAEs as well as non-serious AEs.
| Percentage of participants | Tocilizumab |
|---|---|
| Any AE | 100 |
| SAE | 18.2 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included SAEs as well as non-serious AEs. Causality of AEs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on drug cessation \[DC\], relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AEs with causality of certain, probable/likely, and possible were considered TCZ related.
| Percentage of participants | Tocilizumab |
|---|---|
| Related AE | 72.7 |
| Related SAE | 9.1 |
Adverse events of special interest (AESI) for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events.
| Percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Adverse Events of Special Interest (AESIs) | 18.2 |
AESI for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events. Percentage of participants with AESI related to the drug were presented. Causality of AESIs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on DC, relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AESIs with causality of certain, probable/likely, and possible were considered TCZ related.
| Percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With AESIs Related to TCZ | 18.2 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Percentage of participants with AE causing drug discontinuation, interruption and increase or decrease in dose of drug was presented.
| Percentage of participants | Tocilizumab |
|---|---|
| AE Leading to Discontinuation | 9.1 |
| AE Leading to Interruption | 63.6 |
| AE Leading to Dose Modification | 0.0 |
Criteria for potentially clinically important (PCI) change in vital signs: heart rate value of less than (\<) 40 beats per minute and value greater than (\>) 150 beats per minute, systolic blood pressure (SBP) of \< 80 or \>210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of \<40 or \>130 mmHg, body temperature \<32 or \> 40 degrees Celsius, respiratory rate of \<10 or \> 50 breaths/minute and criteria for PCI change in physical examination: \>/=10% increase or decrease of body weight in kilograms (kg).
| Percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Clinically Significant Physical Examinations and Vital Signs Abnormalities | 0.0 |
Criteria for laboratory tests clinically significant abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(\< 0.8\*lower limit of normal\[LLN\]); leucocytes (\<0.6/greater than \[\>\]1.5\*upper limit of normal \[ULN\]); platelets (\<0.5\*LLN\>\</0\>1.75\*ULN); neutrophils, lymphocytes (\<0.8\*LLN\>\</0\>1.2\*ULN); eosinophils, basophils, monocytes (\>1.2\*ULN); total bilirubin, direct bilirubin, indirect bilirubin (\>1.5\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (\>3\*ULN), total protein, albumin (\<0.8\*LLN\>\</0\>1.2\*ULN); creatinine, urea (\>1.3\*ULN); glucose (\<0.6\*LLN\>\</0\>1.5\*ULN); uric acid (\>1.2\*ULN); sodium, potassium, chloride, calcium, bicarbonate (\<0.9\*LLN\>\</0\>1.1\*ULN); urine RBCs, urine white blood cells (WBCs) (\> or equal\[=\]20 high-powered field), urine bacteria \>20 high-powered field. Overall percentage of participants with any clinically significant laboratory abnormality was reported.
| Percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Clinically Significant Laboratory Abnormalities | 9.1 |
| Percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Anti-TCZ Antibodies | 0.0 |
The DAS 28 ESR score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment (PtGA) of disease activity (visual analog scale \[VAS\]: 0 millimeter \[mm\] = no disease activity to 100 mm=maximum disease activity) and the erythrocyte sedimentation rate (ESR in millimeters per hour \[mm/hr\]). DAS28 was calculated using following formulas: DAS28-ESR = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt (SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PtGA of disease activity. A total possible score of 0 to approximately 10, with higher score indicating more severe disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=11) | 1.81 ± 0.87 |
| Change at Week 12 (n=8) | 0.16 ± 1.59 |
| Change at Week 24 (n=9) | -0.14 ± 1.17 |
| Change at Week 36 (n=9) | -0.02 ± 1.30 |
| Change at Week 48 (n=10) | -0.32 ± 0.93 |
| Change at Week 60 (n=10) | -0.33 ± 1.14 |
| Change at Week 72 (n=10) | -0.35 ± 0.92 |
| Change at Week 84 (n=9) | 0.28 ± 1.23 |
| Change at Week 96 (n=9) | -0.36 ± 1.11 |
| Change at Week 108 (n=7) | -0.14 ± 1.55 |
| Change at Week 120 (n=2) | -0.75 ± 0.88 |
| Change at Completer last visit (n=9) | -0.16 ± 1.19 |
| Change at Early withdrawal (n=2) | 2.76 ± 0.87 |
| Change at Last visit (n=11) | 0.38 ± 1.61 |
The SDAI was calculated as (SJC \[28 joints\] + TJC \[28 joints\] + VAS ptGA + VAS physician global assessment of disease activity + C-reactive Protein (CRP) level in milligram/deciliter \[mg/dL\]). VAS assessments: 0 centimeters (cm)=no disease activity to 10 cm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=5) | 7.21 ± 4.15 |
| Change at Week 12 (n=5) | 9.17 ± 12.63 |
| Change at Week 24 (n=2) | 8.48 ± 7.81 |
| Change at Week 36 (n=3) | 4.50 ± 4.61 |
| Change at Week 48 (n=2) | -1.02 ± 0.23 |
| Change at Week 60 (n=2) | -1.02 ± 1.32 |
| Change at Week 72 (n=3) | 4.19 ± 1.66 |
| Change at Week 84 (n=3) | 0.83 ± 3.43 |
| Change at Week 96 (n=3) | 0.60 ± 4.95 |
| Change at Week 108 (n=3) | 5.25 ± 8.15 |
| Change at Week 120 (n=0) | NA ± NA |
| Change at Completer last visit (n=2) | 0.69 ± 5.02 |
| Change at Early withdrawal (n=1) | 17.38 ± NA |
| Change at Last visit (n=3) | 6.25 ± 10.27 |
For TJC a total of 28 joints were assessed. The presence of a tender joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no tender joint) to 28 (worse possible score or all tender joints). Lower scores indicate no tender joint and higher scores indicate worsening tender joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| Tender Joints | Tocilizumab |
|---|---|
| Baseline (n=11) | 1.27 ± 1.35 |
| Change at Week 12 (n=10) | 0.50 ± 2.27 |
| Change at Week 24 (n=10) | 1.20 ± 3.01 |
| Change at Week 36 (n=10) | 1.00 ± 1.89 |
| Change at Week 48 (n=10) | 0.50 ± 1.84 |
| Change at Week 60 (n=10) | 1.20 ± 5.31 |
| Change at Week 72 (n=10) | 0.60 ± 3.06 |
| Change at Week 84 (n=9) | 0.44 ± 1.51 |
| Change at Week 96 (n=9) | 0.11 ± 1.27 |
| Change at Week 108 (n=7) | 1.57 ± 5.68 |
| Change at Week 120 (n=2) | 0.00 ± 1.41 |
| Change at Completer Last Visit (n=9) | -0.44 ± 1.24 |
| Change at Early Withdrawal n=2) | 6.50 ± 0.71 |
| Change at Last Visit (n=11) | 0.82 ± 3.03 |
For SJC, a total of 28 joints were assessed. The presence of a swollen joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no swollen joint) to 28 (worse possible score or all swollen joints). Lower scores indicate no swollen joint and higher scores indicate worsening swollen joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| Swollen Joints | Tocilizumab |
|---|---|
| Baseline (n=11) | 1.00 ± 1.67 |
| Change at Week 12 (n=10) | 0.50 ± 2.37 |
| Change at Week 24 (n=10) | -0.50 ± 1.84 |
| Change at Week 36 (n=10) | -0.60 ± 2.22 |
| Change at Week 48 (n=10) | -0.80 ± 1.75 |
| Change at Week 60 (n=10) | -0.70 ± 1.49 |
| Change at Week 72 (n=10) | -0.30 ± 2.31 |
| Change at Week 84 (n=9) | -0.78 ± 1.09 |
| Change at Week 96 (n=9) | -0.67 ± 1.41 |
| Change at Week 108 (n=7) | 0.14 ± 2.48 |
| Change at Week 120 (n=2) | -0.50 ± 0.71 |
| Change at Completer Last Visit (n=9) | -0.56 ± 2.24 |
| Change at Early Withdrawal (n=2) | 3.5 ± 2.12 |
| Change at Last Visit (n=11) | 0.18 ± 2.68 |
Clinical remission defined as:DAS28-ESR score \< 2.6 and/or SDAI score \</= 3.3.DAS28 score is measure of subject's disease activity calculated using TJC \[28 joints\],SJC \[28 joints\],PtGA of disease activity \[ VAS:0mm= no disease activity to 100 mm=maximum disease activity\] and ESR (mm/hr). DAS28 was calculated as DAS28-ESR = 0.56\*sqrt (TJC28) + 0.28\*sqrt(SJC28) + 0.70\* ln ESR + 0.014\*PtGA of disease activity. DAS28-ESR score ranged from 0 to approximately 10, higher score indicating more severe disease activity. SDAI was calculated =\[SJC (28 joints) + TJC (28 joints) + VAS PtGA + VAS physician global assessment of disease activity+CRP level(mg/dL)\]. VAS assessments:0 mm=no disease activity to 100 mm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity.
| Percentage of participants | Tocilizumab |
|---|---|
| Week 48 (n=10) | 90 |
| Week 108 (n=8) | 75 |
| Percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Concomitant Corticosteroid Discontinuation | 16.7 |
| Percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Concomitant Corticosteroid Dose Reduction | 50 |
Time to corticosteroid discontinuation = (End date of corticosteroid treatment - date of first drug intake of this extension study) + 1.
| Days | Tocilizumab |
|---|---|
| Time to Concomitant Corticosteroid Discontinuation | 472.00 |
Time to corticosteroid dose reduction (days) = (Date of the first dose reduction of corticosteroid treatment - date of first drug intake of this extension study) + 1.
| Days | Tocilizumab |
|---|---|
| Time to Concomitant Corticosteroid Dose Reduction | 75 (15.0 to 758.0) |
PtGA of disease activity over the previous 24 hours using a 100 mm VAS where left end of the line 0 mm =no disease activity and right end of the line 100 mm =maximum disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| mm | Tocilizumab |
|---|---|
| Baseline (n=11) | 17.55 ± 21.06 |
| Change at Week 12 (n=11) | 11.82 ± 36.19 |
| Change at Week 24 (n=10) | 4.00 ± 12.54 |
| Change at Week 36 (n=10) | 0.90 ± 26.82 |
| Change at Week 48 (n=9) | -4.89 ± 14.16 |
| Change at Week 60 (n=9) | -0.89 ± 20.75 |
| Change at Week 72 (n=9) | -4.44 ± 17.54 |
| Change at Week 84 (n=9) | 0.22 ± 16.17 |
| Change at Week 96 (n=9) | -3.11 ± 16.51 |
| Change at Week 108 (n=7) | -5.00 ± 24.21 |
| Change at Week 120 (n=2) | -21.50 ± 23.33 |
| Change at Completer last visit (n=8) | -6.38 ± 14.48 |
| Change at Early withdrawal (n=2) | 34.00 ± 15.56 |
| Change at Last visit (n=10) | 1.70 ± 21.90 |
Patient's assessment of pain over the previous 24 hours: using a VAS, left end of the line 0 mm=no pain to right end of the line 100 mm=unbearable pain. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| mm | Tocilizumab |
|---|---|
| Baseline (n=11) | 19.18 ± 20.58 |
| Change at Week 12 (n=11) | 10.91 ± 36.68 |
| Change at Week 24 (n=10) | 3.80 ± 14.99 |
| Change at Week 36 (n=10) | -1.90 ± 20.00 |
| Change at Week 48 (n=9) | -6.44 ± 11.57 |
| Change at Week 60 (n=9) | -3.78 ± 15.63 |
| Change at Week 72 (n=9) | -8.11 ± 16.56 |
| Change at Week 84 (n=9) | 0.11 ± 14.44 |
| Change at Week 96 (n=9) | -8.22 ± 13.22 |
| Change at Week 108 (n=7) | -7.86 ± 18.21 |
| Change at Week 120 (n=2) | -20.00 ± 26.87 |
| Change at Completer last visit (n=8) | 1.50 ± 29.71 |
| Change at Early withdrawal (n=2) | 34.50 ± 16.26 |
| Change at Last visit (n=10) | 8.10 ± 30.16 |
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=7) | 0.77 ± 0.55 |
| Change at Week 12 (n=7) | -0.20 ± 0.52 |
| Change at Week 24 (n=7) | 0.18 ± 0.24 |
| Change at Week 36 (n=7) | -0.07 ± 0.31 |
| Change at Week 48 (n=7) | 0.00 ± 0.54 |
| Change at Week 60 (n=7) | -0.13 ± 0.35 |
| Change at Week 72 (n=6) | -0.25 ± 0.41 |
| Change at Week 84 (n=5) | -0.18 ± 0.62 |
| Change at Week 96 (n=5) | 0.08 ± 0.07 |
| Change at Week 108 (n=5) | -0.15 ± 0.57 |
| Change at Week 120 (n=1) | 0.00 ± NA |
| Change at Completer Last Visit (n=6) | 0.10 ± 0.43 |
| Change at Early Withdrawal (n=1) | 0.00 ± NA |
| Change at Last Visit (n=7) | 0.09 ± 0.39 |
The Physician's Global Assessment of disease activity was assessed using a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity". Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| mm | Tocilizumab |
|---|---|
| Baseline (n=10) | 11.00 ± 10.84 |
| Change at Week 12 (n=10) | 17.60 ± 31.71 |
| Change at Week 24 (n=9) | 5.22 ± 12.37 |
| Change at Week 36 (n=9) | 2.22 ± 17.23 |
| Change at Week 48 (n=9) | -4.11 ± 7.10 |
| Change at Week 60 (n=8) | -2.13 ± 6.06 |
| Change at Week 72 (n=8) | -0.75 ± 7.87 |
| Change at Week 84 (n=9) | 1.22 ± 9.80 |
| Change at Week 96 (n=8) | 2.00 ± 19.25 |
| Change at Week 108 (n=7) | 1.00 ± 6.90 |
| Change at Week 120 (n=2) | 2.5 ± 7.78 |
| Change at Completer last visit (n=7) | 6.71 ± 13.0 |
| Change at Early withdrawal (n=2) | 36.5 ± 10.61 |
| Change at Last visit (n=9) | 13.33 ± 17.70 |
Blood samples were collected for ESR, which is an acute phase reactant and provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeters per hour (mm/hr). A decrease in the level indicates reduction in inflammation and therefore improvement. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| mm/hr | Tocilizumab |
|---|---|
| Baseline (n=11) | 5.82 ± 7.26 |
| Change at Week 12 (n=9) | -2.44 ± 8.34 |
| Change at Week 24 (n=9) | -3.11 ± 8.30 |
| Change at Week 36 (n=9) | 1.89 ± 17.22 |
| Change at Week 48 (n=10) | 0.90 ± 10.21 |
| Change at Week 60 (n=10) | -0.10 ± 12.64 |
| Change at Week 72 (n=10) | -2.60 ± 7.66 |
| Change at Week 84 (n=10) | 2.80 ± 11.82 |
| Change at Week 96 (n=9) | -1.22 ± 9.97 |
| Change at Week 108 (n=7) | 3.29 ± 21.34 |
| Change at Week 120 (n=2) | -0.50 ± 0.71 |
| Change at Completer last visit (n=9) | 2.22 ± 6.55 |
| Change at Early withdrawal (n=2) | 14.00 ± 15.56 |
| Change at Last visit (n=11) | 4.36 ± 9.01 |
Blood samples were collected for CRP, which is an acute phase reactant and a measure of inflammation. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.
| milligrams per liter (mg/L) | Tocilizumab |
|---|---|
| Baseline (n=5) | 0.49 ± 0.47 |
| Change at Week 12 (n=5) | 1.07 ± 2.17 |
| Change at Week 24 (n=2) | -0.25 ± 0.35 |
| Change at Week 36 (n=3) | -0.02 ± 0.52 |
| Change at Week 48 (n=3) | -0.05 ± 0.65 |
| Change at Week 60 (n=3) | -0.09 ± 0.66 |
| Change at Week 72 (n=3) | -0.05 ± 0.61 |
| Change at Week 84 (n=3) | -0.05 ± 0.51 |
| Change at Week 96 (n=3) | -0.02 ± 0.62 |
| Change at Week 108 (n=3) | 1.55 ± 2.13 |
| Change at Week 120 (n=0) | NA ± NA |
| Change at Completer last visit (n=3) | 0.01 ± 0.54 |
| change at Early withdrawal (n=1) | 4.79 ± NA |
| Change at Last visit (n=4) | 1.21 ± 2.43 |
Collected over Baseline up to approximately 142 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 2/11 (18.2%) | 11/11 (100%) |
| Event | Tocilizumab |
|---|---|
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/11 |
| Inflammatory pseudotumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/11 |
| Extremity necrosisVascular disorders | 1/11 |
| Event | Tocilizumab |
|---|---|
| BronchitisInfections and infestations | 5/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/11 |
| Urinary tract infectionInfections and infestations | 3/11 |
| NasopharyngitisInfections and infestations | 2/11 |
| RhinitisInfections and infestations | 2/11 |
| SinusitisInfections and infestations | 2/11 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/11 |
| GastroenteritisInfections and infestations | 1/11 |
| InfluenzaInfections and infestations | 1/11 |
| Oral herpesInfections and infestations | 1/11 |
Safety population included all participants who received at least one dose of study medication.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 63.91 ± 11.96 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 7 |
| Male | 4 |
The record gives a start of Oct 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab